Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of “Buy” from Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been given an average rating of “Buy” by the eight analysts that are currently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have issued a report on the stock in the last year is $9.00.

PYXS has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research note on Friday, August 16th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Thursday, September 19th. Finally, Stifel Nicolaus assumed coverage on Pyxis Oncology in a research report on Thursday, August 8th. They issued a “buy” rating and a $10.00 target price for the company.

Pyxis Oncology Stock Performance

Shares of PYXS stock opened at $3.54 on Friday. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The firm has a market cap of $208.46 million, a P/E ratio of -2.60 and a beta of 1.27. The business’s 50 day moving average price is $3.58 and its 200-day moving average price is $3.86.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. As a group, equities analysts predict that Pyxis Oncology will post -1.07 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in PYXS. StemPoint Capital LP bought a new stake in shares of Pyxis Oncology in the 1st quarter worth approximately $7,643,000. Ikarian Capital LLC purchased a new position in Pyxis Oncology during the first quarter valued at $7,082,000. Vanguard Group Inc. boosted its holdings in Pyxis Oncology by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock worth $5,970,000 after acquiring an additional 94,740 shares in the last quarter. Millennium Management LLC grew its stake in shares of Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after acquiring an additional 743,499 shares during the last quarter. Finally, Blue Owl Capital Holdings LP bought a new position in shares of Pyxis Oncology during the second quarter valued at $3,462,000. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.